AR053596A1 - Forma polimorfa ii de tanaproget - Google Patents

Forma polimorfa ii de tanaproget

Info

Publication number
AR053596A1
AR053596A1 ARP060101668A ARP060101668A AR053596A1 AR 053596 A1 AR053596 A1 AR 053596A1 AR P060101668 A ARP060101668 A AR P060101668A AR P060101668 A ARP060101668 A AR P060101668A AR 053596 A1 AR053596 A1 AR 053596A1
Authority
AR
Argentina
Prior art keywords
degree
tanaproget
polymorph
lacks
tanaproget polymorph
Prior art date
Application number
ARP060101668A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR053596A1 publication Critical patent/AR053596A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Procesos para preparar la Forma II del polimorfo de tanaproget, composiciones farmacéuticas que incluyen a la Forma II del polimorfo de tanaproget, la Forma II micronizada del polimorfo de tanaproget, y procesos para convertir la Forma II en la Forma I de tanaproget. También se proporcionan métodos de contracepcion, terapia de reemplazo hormonal, estimulacion de la ingesta de alimentos y tratar o prevenir los fibroides miometriales uterinos, hipertrofia prostática benigna, enfermedad neoplásica benigna y maligna, sangrado disfuncional leiomioma uterino, endometriosis, síndrome de ovario policístico, o carcinomas y adenocarcinomas que comprende administrar la Forma II polimorfica a un sujeto mamífero. Reivindicacion 1: Una Forma II de polimorfo de tanaproget que tiene: (a) un termograma de calorimetría por exploracion diferencial que carece de un pico endotérmico de 230 degree C; y (b) un patron de difraccion de rayos X que carece de picos en 2theta de 6,6 degree , 10,3 degree , 14,4 degree , 19,8 degree , 23,8 degree , 26,3 degree y 29,1 degree .
ARP060101668A 2005-04-28 2006-04-26 Forma polimorfa ii de tanaproget AR053596A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67573705P 2005-04-28 2005-04-28

Publications (1)

Publication Number Publication Date
AR053596A1 true AR053596A1 (es) 2007-05-09

Family

ID=36954854

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101668A AR053596A1 (es) 2005-04-28 2006-04-26 Forma polimorfa ii de tanaproget

Country Status (11)

Country Link
US (4) US7759341B2 (es)
EP (1) EP1874763A2 (es)
JP (2) JP2008539258A (es)
CN (1) CN101166736B (es)
AR (1) AR053596A1 (es)
AU (1) AU2006241125B2 (es)
BR (1) BRPI0610433A2 (es)
CA (1) CA2603807A1 (es)
MX (1) MX2007013469A (es)
TW (1) TW200716621A (es)
WO (1) WO2006116526A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2383525T3 (es) 2003-11-05 2012-06-21 Sarcode Bioscience Inc. Moduladores de la adhesión celular
DE602006007453D1 (de) 2005-04-28 2009-08-06 Wyeth Corp Zusammensetzungen mit mikronisiertem tanaproget
CN101166533A (zh) 2005-04-28 2008-04-23 惠氏公司 微粉化的tanaproget和含有它的组合物
US7767668B2 (en) * 2005-04-28 2010-08-03 Wyeth Llc Micronized tanaproget, compositions, and methods of preparing the same
BRPI0610433A2 (pt) * 2005-04-28 2010-11-23 Wyeth Corp forma polimórfica ii de tanaproget, processos para preparar a mesma, e para preparar forma micronizada de um composto, composição farmacêutica, método de preparação de uma composição farmacêutica, e, uso da forma polimórfica ii de tanaproget ou da forma micronizada
CA2610767C (en) 2005-06-09 2014-09-23 Wyeth Tanaproget compositions containing ethinyl estradiol
JP2011507853A (ja) 2007-12-20 2011-03-10 テバ ウィメンズ ヘルス インコーポレイテッド 緊急避妊のための投与量レジメンならびに薬学的組成物およびパッケージ
US20110237605A1 (en) * 2010-03-26 2011-09-29 Eric Phillips Molecular Crystal of (4-(1,8-Naphthyridin-2-YL)Piperidin-1-YL)Pyrimidine Derivative
HUE030526T2 (en) 2012-06-13 2017-05-29 Hoffmann La Roche New diazaspirocycloalkane and azaspirocycloalkane
KR102157608B1 (ko) 2012-07-25 2020-09-18 에스에이알코드 바이오사이언스 인코포레이티드 Lfa-1 저해제 및 그의 다형체
SG11201500572YA (en) 2012-09-25 2015-02-27 Hoffmann La Roche New bicyclic derivatives
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
EA201691044A1 (ru) 2013-11-26 2016-09-30 Ф. Хоффманн-Ля Рош Аг Новый октагидро-циклобута[1,2-c;3,4-c']дипиррол-2-ил
LT3122750T (lt) 2014-03-26 2019-11-11 Hoffmann La Roche Biciklinių junginių, tokių kaip autotaksino (atx) ir lizofosfatidinės rūgšties (lpa), gamybos inhibitoriai
UA119347C2 (uk) 2014-03-26 2019-06-10 Ф. Хоффманн-Ля Рош Аг Конденсовані [1,4]діазепінові сполуки як інгібітори продукції аутотаксину (atх) та лізофосфатидилової кислоти (lpa)
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
CN108026077B (zh) 2015-09-04 2021-11-05 豪夫迈·罗氏有限公司 苯氧基甲基衍生物
KR20180054635A (ko) 2015-09-24 2018-05-24 에프. 호프만-라 로슈 아게 오토탁신(atx) 억제제로서 이환형 화합물
MA42918A (fr) 2015-09-24 2018-08-01 Hoffmann La Roche Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
RU2724899C2 (ru) 2015-09-24 2020-06-26 Ф. Хоффманн-Ля Рош Аг Новые бициклические соединения в качестве дуальных ингибиторов atx/ca
CR20180143A (es) 2015-09-24 2018-05-03 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de atx/ca
EP3596060B1 (en) 2017-03-16 2023-09-20 F. Hoffmann-La Roche AG New bicyclic compounds as atx inhibitors
KR20190129924A (ko) 2017-03-16 2019-11-20 에프. 호프만-라 로슈 아게 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서 유용한 헤테로환형 화합물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01011287A (es) * 1999-05-04 2003-07-14 American Home Prod Derivados de ciclotiocarbamato como moduladores de receptor de progesterona.
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
JP2005535628A (ja) 2002-06-25 2005-11-24 ワイス Ｐｒモジュレーターとしてのシクロチオカルバメート誘導体
JP2005535624A (ja) 2002-06-25 2005-11-24 ワイス ホルモン関連症状の治療におけるシクロチオカルバメート誘導体の使用
US8399013B2 (en) * 2003-06-26 2013-03-19 Poly-Med, Inc. Partially absorbable fiber-reinforced composites for controlled drug delivery
AR049631A1 (es) 2004-04-27 2006-08-23 Wyeth Corp Proceso de acoplamiento para la generacion de derivados reactivos de pirrol -2- carbonitrilo n- sustituidos con contenido de boro para producir biarilos
CN1953967B (zh) * 2004-04-27 2013-03-13 惠氏公司 孕酮受体调节剂的纯化
JP4980217B2 (ja) 2004-08-13 2012-07-18 ワイス・エルエルシー タナプロゲト誘導体、代謝産物、及びそれらの使用
US7786297B2 (en) * 2005-04-28 2010-08-31 Wyeth Llc Purified form of tanaproget
US7767668B2 (en) * 2005-04-28 2010-08-03 Wyeth Llc Micronized tanaproget, compositions, and methods of preparing the same
DE602006007453D1 (de) * 2005-04-28 2009-08-06 Wyeth Corp Zusammensetzungen mit mikronisiertem tanaproget
CN101166533A (zh) * 2005-04-28 2008-04-23 惠氏公司 微粉化的tanaproget和含有它的组合物
BRPI0610433A2 (pt) * 2005-04-28 2010-11-23 Wyeth Corp forma polimórfica ii de tanaproget, processos para preparar a mesma, e para preparar forma micronizada de um composto, composição farmacêutica, método de preparação de uma composição farmacêutica, e, uso da forma polimórfica ii de tanaproget ou da forma micronizada
CA2610767C (en) * 2005-06-09 2014-09-23 Wyeth Tanaproget compositions containing ethinyl estradiol

Also Published As

Publication number Publication date
AU2006241125A1 (en) 2006-11-02
US20060247235A1 (en) 2006-11-02
US8114869B2 (en) 2012-02-14
JP2014088385A (ja) 2014-05-15
CN101166736B (zh) 2013-02-06
US7759341B2 (en) 2010-07-20
WO2006116526A8 (en) 2007-08-16
CN101166736A (zh) 2008-04-23
TW200716621A (en) 2007-05-01
JP2008539258A (ja) 2008-11-13
EP1874763A2 (en) 2008-01-09
AU2006241125B2 (en) 2012-07-05
US20110212953A1 (en) 2011-09-01
BRPI0610433A2 (pt) 2010-11-23
WO2006116526A2 (en) 2006-11-02
CA2603807A1 (en) 2006-11-02
US7968709B2 (en) 2011-06-28
MX2007013469A (es) 2008-01-22
US20100267715A1 (en) 2010-10-21
US20120115858A1 (en) 2012-05-10
WO2006116526A3 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
AR053596A1 (es) Forma polimorfa ii de tanaproget
AR056328A1 (es) TANAPROGET MICRONIZADO, COMPOSICIONES Y MÉTODOS PARA SU PREPARACIoN
CY1110017T1 (el) Μικρονισμενη ταναπρογετη και συνθεσεις που περιεχουν αυτην
TW200731969A (en) Use of progesterone receptor modulators
DK1874278T3 (da) Sammensætninger indeholdende mikroniseret tanaproget
JP2008539258A5 (es)
PA8513801A1 (es) Acidos malonamicos y derivados de los mismos como ligandos de receptor tiroideo
ES2172579T3 (es) Agonistas/antagonistas de estrogenos.
CY1106610T1 (el) Μεθοδος για την προληψη ή την θεραπευτικη αντιμετωπιση καλοηθων γυναικολογικων διαταραχων
CO4810234A1 (es) Vacunas para el tratamiento de virus papiloma humano
ES2152671T3 (es) Derivados de progesterona sustituidos en posicion 21 como nuevos agentes antiprogestacionales.
ATE515493T1 (de) Mercaptophenylnaphthylmethan-derivate und deren herstellung
DE602005019905D1 (de) -modulatoren
NZ515353A (en) Cyclothiocarbamate derivatives as progesterone receptor modulators
ECSP078043A (es) Derivados de benzofurarona como moduladores no esteroides de receptores de progesterona
DOP2006000147A (es) Uso de modulares no esteroides de receptores de progesterona.
CR9598A (es) Moduladores no esteroides de receptor de progesterona
MX2009009515A (es) Cianopirrol sulfonamidas utiles para la modulacion del receptor de progesterona.
PE20090167A1 (es) Sintesis y caracterizacion de la forma iii polimorfica de 4-(2-(4,4-dimetil-2-oxooxazolidin-3-il)tiazol-4-il)benzonitrilo
CY1109919T1 (el) Παραγωγα της ινδολης που ειναι χρησιμα σα ρυθμιστες του υποδοχεα της προγεστερονης
ES2128635T3 (es) Procedimiento para la obtencion de sulfanos de 2-cloro-6-nitrofenil-alquilo, y nuevos sulfanos de 2-cloro-6-nitrofenilalquilo.
JP5735122B2 (ja) 抗癌活性を有するベンズアミド誘導体並びにその製造方法および使用
PA8771701A1 (es) Síntesis y caracterización de la forma ii polimórfica de 4-(4,-dimetil-2oxooxazolidin--il)tiazol-4il)benzonitrilo"
RU2016100028A (ru) Полиморфные формы икотиниба и их применения
Twum Development of Prodrugs to Deliver Super-potent Drugs to Prostate Tumours

Legal Events

Date Code Title Description
FA Abandonment or withdrawal